Last reviewed · How we verify
NCT03869151
Pretreatment Lymphocyte Monocyte Ratio on Outcome HCC Patients
trial testing CBC in Hepatocellular Carcinoma in 1 participant. Status unknown.
5 March 2020
Quick facts
| Lead sponsor | Amany Aboalenen Amin |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1 |
| Start date | 5 April 2019 |
| Primary completion | 5 March 2020 |
| Estimated completion | 31 March 2020 |
Drugs / interventions tested
- CBC
Conditions studied
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Sponsor
Amany Aboalenen Amin
Who can join
Adults 20 to 80, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the prognostic role of pretreatment LMR in hepatocellular carcinoma(HCC).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cellular based immunotherapy for primary liver cancer.
Zheng Y, Li Y, Feng J, Li J, et al · · 2021 · cited 24× · PMID 34372912 · DOI 10.1186/s13046-021-02030-5
Verify or expand the search:
- PubMed search for NCT03869151
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CBC
Trials testing the same drug.
- NCT07479563 — Modified Shock Index · not yet recruiting
- NCT06568913 — The Outcome of the Thrombopoietin Receptor Agonists in Pediatric Patient With Persistent or Chronic ITP Unresonsive to S · NA · recruiting
- NCT06491667 — NLR AND CRP Useful as Cost-Effective Preliminary Prognostic Markers in ST-Elevation Myocardial Infarction · recruiting
- NCT06294483 — Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. · unknown
- NCT05997108 — Platelet and Red Blood Cell Volume Indices as Inflammatory Biomarkers in Ankylosing Spondylitis · unknown
Other recruiting trials for Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
- NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03869151 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Amany Aboalenen Amin
- Last refreshed: 2 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03869151.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing